论文部分内容阅读
二氢咪唑酮衍生物Enoximone抑制磷酸二酯酶从而提高细胞内cAMP水平,兼有正性肌力和血管扩张作用。本文报道30例慢性充血性心力衰竭患者长期口服Enoximone的疗效和安全性。西德组14例患者(A组)的平均年龄49(24～63)岁,其中特发性扩张型心肌病12例、缺血性心脏病和瓣膜性心脏病2例,心功能NYHA Ⅲ(或Ⅳ)级。英国组16例患者(B组)的平均年龄54.5(48～68)岁,其中缺血性心脏病11例、扩张型心肌病5例,心功能
Dihydroimidazolone derivatives Enoximone inhibits phosphodiesterase thereby increasing intracellular cAMP levels, both positive inotropic and vasodilating effect. This article reports the efficacy and safety of long-term oral administration of Enoximone in 30 patients with chronic congestive heart failure. The mean age was 49 (24-63) years in 14 patients in the West Germany group (A group), including 12 patients with idiopathic dilated cardiomyopathy, 2 with ischemic heart disease and valvular heart disease, 2 with NYHA III Or Ⅳ) level. The average age of 16 patients (group B) in the UK group was 54.5 (48-68) years, including 11 with ischemic heart disease, 5 with dilated cardiomyopathy,